← 홈

폐암 (NSCLC)

291개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 291개
CGTBiologicstaleBellicum PharmaceuticalsPhase 1

iC9.GD2.CAR.IL-15 T Infusion (iC9.GD2.CAR.IL-15 T Infusion)

Lung Cancer; Small Cell Lung Carcinoma · GD2

#GD2#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

pembrolizumab (Keytruda, ipilimumab +pembrolizumab +durvalumab)

Lung Cancer; Liver Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleMt. Sinai Medical Center, MiamiPhase 2

oxaliplatin, gemcitabine, bevacizumab (oxaliplatin, gemcitabine, bevacizumab)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleSpanish Lung Cancer GroupPreclinical

paclitaxel, carboplatin and bevacizumab (paclitaxel, carboplatin and bevacizumab)

Nonsquamous Nonsmall Cell Neoplasm of Lung · Nonsquamous Nonsmall Cell Neoplasm of Lu

#NonsquamousNonsmallCellNeoplasmo#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleShanghai Cancer Hospital, ChinaPhase 2

durvalumab (Imfinzi, pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT)

Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, pertuzumab + trastuzumab + docetaxel)

Non Small Cell Lung Cancer Metastatic; Non Small Cell Lung Cancer Stage III · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleMemorial Sloan Kettering Cancer…Phase 2

pilimumab (pilimumab)

Advanced Stage Non-small Cell Lung Cancer · Advanced Stage Non-small Cell Lung Cance

#AdvancedStageNon-smallCellLungCa#Antibody#Phase2#항체#면역항체+2
효능 ORR 7%임상시험 1상태 ACTIVE
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

sac-TMT (sac-TMT)

Non-small Cell Lung Cancer; NSCLC · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleCancer Institute and Hospital, …Phase 2

Almonertinib/Furmonertinib/Osimertinib (third-generation EGFR TKIs, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib))

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · EGFR

#EGFR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 3

anti-CTLA4 (tremelimumab, tremelimumab (anti-CTLA4))

Non - Small Cell Lung Cancer NSCLC · Non - Small Cell Lung Cancer NSCLC

#Non-SmallCellLungCancerNSCLC#Antibody#Phase3#항체#면역항체+2
효능 ORR 35.5%임상시험 1상태 ACTIVE
CGTBiologicstaleSichuan UniversityPhase 1

BHP01 (α-PD-L1/4-1BB DLL3 CAR-T, α-PD-L1/4-1BB DLL3 CAR-T (BHP01))

Small Cell Lung Cancer Extensive Stage · PD-L1

#PD-L1#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING

15 / 15 페이지

← 이전다음 →